PSMA (Prostate-Specific Membrane Antigen) targeted diagnostics and therapy — the theranostic platform using PSMA-targeting molecules for both PET imaging (diagnosis, staging) and radioligand therapy (treatment) — represents the most commercially transformative recent development in prostate cancer, with the Prostate Cancer Market reflecting PSMA theranostics as the highest commercial growth driver.

Lutetium-177 PSMA (Pluvicto, Novartis) — the FDA-approved radioligand therapy delivering beta-particle radiation directly to PSMA-expressing prostate cancer cells — representing a landmark approval for metastatic castration-resistant prostate cancer. The VISION trial demonstrating significant OS improvement (15.3 vs 11.3 months) and PFS improvement combined with the companion diagnostic requirement creating the commercial theranostic ecosystem. Novartis reporting Pluvicto approaching two billion dollars in annual revenue within two years of launch demonstrating the extraordinary commercial acceptance.

PSMA-PET imaging (Pylarify, Ga-68 PSMA-11) — the FDA-cleared diagnostic imaging agents enabling highly sensitive PSMA PET staging — creating the prerequisite diagnostic market for PSMA therapy patient selection. The PSMA PET's superior sensitivity versus conventional bone scan and CT for metastatic disease detection changing the prostate cancer staging landscape and identifying more patients eligible for PSMA-targeted therapy.

Next-generation PSMA radiopharmaceuticals — the Actinium-225 PSMA (alpha particle emitter, more potent), BiTE antibodies targeting PSMA, and CAR-T cells targeting PSMA — represent the pipeline expanding the PSMA treatment landscape. The Bi-213 and Ac-225 alpha emitter PSMA programs in clinical development potentially providing more potent tumor killing for PSMA-expressing lesions.

Do you think PSMA theranostics will become first-line treatment for metastatic prostate cancer, challenging the primacy of second-generation androgen receptor pathway inhibitors (enzalutamide, abiraterone)?

FAQ

What is Lutetium-177 PSMA (Pluvicto) and how does it work? Pluvicto (lutetium PSMA-617): FDA approved March 2022 for PSMA-positive mCRPC previously treated with androgen receptor pathway inhibitor and taxane-based chemotherapy; mechanism: PSMA-617 targeting ligand delivers Lu-177 beta emitter to PSMA-expressing prostate cancer cells; targeted beta radiation causing DNA double-strand breaks; VISION trial: radiographic PFS 8.7 vs 3.4 months, OS 15.3 vs 11.3 months; treatment: six cycles every six weeks IV infusion; requires prior PSMA-PET positive scan; side effects: dry mouth (salivary glands PSMA-expressing), fatigue, nausea; significant commercial success for Novartis ($1.7 billion 2023 revenue).

What PSMA-PET imaging agents are FDA approved? Piflufolastat F18 (Pylarify, Lantheus): F-18 labeled; eighteen-minute half-life; centralized production and distribution; FDA approved May 2021; OSPREY and CONDOR trials supporting approval; Gallium-68 PSMA-11 (UCLA/UCSF preparation): Ga-68 labeled; sixty-eight minute half-life; on-site cyclotron or generator production; FDA approved December 2020; commercial advantages Pylarify (F-18): longer shelf life, centralized production, wider distribution; clinical application: initial staging high-risk localized; biochemical recurrence after local treatment; metastatic disease characterization; Pluvicto patient selection (VISION trial required PSMA PET eligibility).

#ProstateCancer #PSMAtheranostics #Pluvicto #LutetiumPSMA #PSMApet #Pylarify